lyostar 3 (ATS Scientific Inc)
ATS Scientific Inc is a verified supplier 
ATS Scientific Inc manufactures this product 
96
Structured Review
ATS Scientific Inc
lyostar 3
Lyostar 3, supplied by ATS Scientific Inc, used in various techniques. Bioz Stars score: 96/100, based on 403 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lyostar+3/Hull+LyoStar+4%2E0+R%26D%2FProcess+Development+Freeze+Dryer/10__1186_slash_s41120___026___00147___5-59-8-8
Average 96 stars, based on 403 article reviews
Lyostar 3, supplied by ATS Scientific Inc, used in various techniques. Bioz Stars score: 96/100, based on 403 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lyostar+3/Hull+LyoStar+4%2E0+R%26D%2FProcess+Development+Freeze+Dryer/10__1186_slash_s41120___026___00147___5-59-8-8
Average 96 stars, based on 403 article reviews
lyostar 3 - by Bioz Stars,
2026-10
96/100 stars
Images
Related Articles
Comparison:Article Title: Lyophilization to enable distribution of ChAdOx1 and ChAdOx2 adenovirus-vectored vaccines without refrigeration Article Snippet: .. Samples were dried using cycle A (Supplementary Data, sheet ) in Article Title: Lyophilization to enable distribution of ChAdOx1 and ChAdOx2 adenovirus-vectored vaccines without refrigeration. Article Snippet: .. Samples were dried using cycle A (Supplementary Data, sheet 2) in Infection:Article Title: Lyophilization to enable distribution of ChAdOx1 and ChAdOx2 adenovirus-vectored vaccines without refrigeration Article Snippet: .. Samples were dried using cycle A (Supplementary Data, sheet ) in Article Title: Lyophilization to enable distribution of ChAdOx1 and ChAdOx2 adenovirus-vectored vaccines without refrigeration. Article Snippet: .. Samples were dried using cycle A (Supplementary Data, sheet 2) in Fluorescence:Article Title: Lyophilization to enable distribution of ChAdOx1 and ChAdOx2 adenovirus-vectored vaccines without refrigeration Article Snippet: .. Points indicate mean measurements and error bars indicate standard error of the mean of 3 replicate samplings from a single reconstitute well (D) Particle size (represented as DLS Z-average) (E) Protein melting temperature (Tm, inferred from change in barycentric mean of intrinsic fluorescence during a temperature ramp) (F) Concentration of genome-containing virus particles, derived from UV spectrophotometry of SDS-treated solutions. stability and cake morphology (A) Cake morphology in plates with and without annealing +/- enhanced primary drying. (B) Cake morphology in vials after lyophilization with (top) and without (bottom) annealing ramp drying with varying fill depths Vials were filled with a range of volumes formulation TSM2 containing ChAdOx1 luciferase at 1x1011 VP/mL, or with 200 μL at 3.25x1011 VP/mL, and subjected to lyophilization using a cycle combining annealing with a slow temperature ramp during drying (Cycle E) in the Concentration Assay:Article Title: Lyophilization to enable distribution of ChAdOx1 and ChAdOx2 adenovirus-vectored vaccines without refrigeration Article Snippet: .. Points indicate mean measurements and error bars indicate standard error of the mean of 3 replicate samplings from a single reconstitute well (D) Particle size (represented as DLS Z-average) (E) Protein melting temperature (Tm, inferred from change in barycentric mean of intrinsic fluorescence during a temperature ramp) (F) Concentration of genome-containing virus particles, derived from UV spectrophotometry of SDS-treated solutions. stability and cake morphology (A) Cake morphology in plates with and without annealing +/- enhanced primary drying. (B) Cake morphology in vials after lyophilization with (top) and without (bottom) annealing ramp drying with varying fill depths Vials were filled with a range of volumes formulation TSM2 containing ChAdOx1 luciferase at 1x1011 VP/mL, or with 200 μL at 3.25x1011 VP/mL, and subjected to lyophilization using a cycle combining annealing with a slow temperature ramp during drying (Cycle E) in the Virus:Article Title: Lyophilization to enable distribution of ChAdOx1 and ChAdOx2 adenovirus-vectored vaccines without refrigeration Article Snippet: .. Points indicate mean measurements and error bars indicate standard error of the mean of 3 replicate samplings from a single reconstitute well (D) Particle size (represented as DLS Z-average) (E) Protein melting temperature (Tm, inferred from change in barycentric mean of intrinsic fluorescence during a temperature ramp) (F) Concentration of genome-containing virus particles, derived from UV spectrophotometry of SDS-treated solutions. stability and cake morphology (A) Cake morphology in plates with and without annealing +/- enhanced primary drying. (B) Cake morphology in vials after lyophilization with (top) and without (bottom) annealing ramp drying with varying fill depths Vials were filled with a range of volumes formulation TSM2 containing ChAdOx1 luciferase at 1x1011 VP/mL, or with 200 μL at 3.25x1011 VP/mL, and subjected to lyophilization using a cycle combining annealing with a slow temperature ramp during drying (Cycle E) in the Derivative Assay:Article Title: Lyophilization to enable distribution of ChAdOx1 and ChAdOx2 adenovirus-vectored vaccines without refrigeration Article Snippet: .. Points indicate mean measurements and error bars indicate standard error of the mean of 3 replicate samplings from a single reconstitute well (D) Particle size (represented as DLS Z-average) (E) Protein melting temperature (Tm, inferred from change in barycentric mean of intrinsic fluorescence during a temperature ramp) (F) Concentration of genome-containing virus particles, derived from UV spectrophotometry of SDS-treated solutions. stability and cake morphology (A) Cake morphology in plates with and without annealing +/- enhanced primary drying. (B) Cake morphology in vials after lyophilization with (top) and without (bottom) annealing ramp drying with varying fill depths Vials were filled with a range of volumes formulation TSM2 containing ChAdOx1 luciferase at 1x1011 VP/mL, or with 200 μL at 3.25x1011 VP/mL, and subjected to lyophilization using a cycle combining annealing with a slow temperature ramp during drying (Cycle E) in the Spectrophotometry:Article Title: Lyophilization to enable distribution of ChAdOx1 and ChAdOx2 adenovirus-vectored vaccines without refrigeration Article Snippet: .. Points indicate mean measurements and error bars indicate standard error of the mean of 3 replicate samplings from a single reconstitute well (D) Particle size (represented as DLS Z-average) (E) Protein melting temperature (Tm, inferred from change in barycentric mean of intrinsic fluorescence during a temperature ramp) (F) Concentration of genome-containing virus particles, derived from UV spectrophotometry of SDS-treated solutions. stability and cake morphology (A) Cake morphology in plates with and without annealing +/- enhanced primary drying. (B) Cake morphology in vials after lyophilization with (top) and without (bottom) annealing ramp drying with varying fill depths Vials were filled with a range of volumes formulation TSM2 containing ChAdOx1 luciferase at 1x1011 VP/mL, or with 200 μL at 3.25x1011 VP/mL, and subjected to lyophilization using a cycle combining annealing with a slow temperature ramp during drying (Cycle E) in the Lyophilization:Article Title: Lyophilization to enable distribution of ChAdOx1 and ChAdOx2 adenovirus-vectored vaccines without refrigeration Article Snippet: .. Points indicate mean measurements and error bars indicate standard error of the mean of 3 replicate samplings from a single reconstitute well (D) Particle size (represented as DLS Z-average) (E) Protein melting temperature (Tm, inferred from change in barycentric mean of intrinsic fluorescence during a temperature ramp) (F) Concentration of genome-containing virus particles, derived from UV spectrophotometry of SDS-treated solutions. stability and cake morphology (A) Cake morphology in plates with and without annealing +/- enhanced primary drying. (B) Cake morphology in vials after lyophilization with (top) and without (bottom) annealing ramp drying with varying fill depths Vials were filled with a range of volumes formulation TSM2 containing ChAdOx1 luciferase at 1x1011 VP/mL, or with 200 μL at 3.25x1011 VP/mL, and subjected to lyophilization using a cycle combining annealing with a slow temperature ramp during drying (Cycle E) in the Formulation:Article Title: Lyophilization to enable distribution of ChAdOx1 and ChAdOx2 adenovirus-vectored vaccines without refrigeration Article Snippet: .. Points indicate mean measurements and error bars indicate standard error of the mean of 3 replicate samplings from a single reconstitute well (D) Particle size (represented as DLS Z-average) (E) Protein melting temperature (Tm, inferred from change in barycentric mean of intrinsic fluorescence during a temperature ramp) (F) Concentration of genome-containing virus particles, derived from UV spectrophotometry of SDS-treated solutions. stability and cake morphology (A) Cake morphology in plates with and without annealing +/- enhanced primary drying. (B) Cake morphology in vials after lyophilization with (top) and without (bottom) annealing ramp drying with varying fill depths Vials were filled with a range of volumes formulation TSM2 containing ChAdOx1 luciferase at 1x1011 VP/mL, or with 200 μL at 3.25x1011 VP/mL, and subjected to lyophilization using a cycle combining annealing with a slow temperature ramp during drying (Cycle E) in the Luciferase:Article Title: Lyophilization to enable distribution of ChAdOx1 and ChAdOx2 adenovirus-vectored vaccines without refrigeration Article Snippet: .. Points indicate mean measurements and error bars indicate standard error of the mean of 3 replicate samplings from a single reconstitute well (D) Particle size (represented as DLS Z-average) (E) Protein melting temperature (Tm, inferred from change in barycentric mean of intrinsic fluorescence during a temperature ramp) (F) Concentration of genome-containing virus particles, derived from UV spectrophotometry of SDS-treated solutions. stability and cake morphology (A) Cake morphology in plates with and without annealing +/- enhanced primary drying. (B) Cake morphology in vials after lyophilization with (top) and without (bottom) annealing ramp drying with varying fill depths Vials were filled with a range of volumes formulation TSM2 containing ChAdOx1 luciferase at 1x1011 VP/mL, or with 200 μL at 3.25x1011 VP/mL, and subjected to lyophilization using a cycle combining annealing with a slow temperature ramp during drying (Cycle E) in the |
![A photograph (left) and schematic (right) of qRF microwave lyophilization experimental setup on LyoStar <t>\documentclass[12pt]{minimal}</t> \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\circledR$$\end{document} 3 freeze-dryer. Closed-loop components are marked in green.](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_0371/pmc11950371/pmc11950371__41598_2025_91642_Fig1_HTML.jpg)
![The normalized electric field distribution inside the qRF microwave chamber based on full-wave electromagnetic simulations using COMSOL for scatterer rotation angle \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\theta =0$$\end{document} and 152 degrees and excitation frequencies \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$f=2.5$$\end{document} and 8 GHz.](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_0371/pmc11950371/pmc11950371__41598_2025_91642_Fig3_HTML.jpg)
![Experimentally measured temperatures, ( a ) and ( b ), and pressures, ( c ), for Cases M1, ( a ) and ( c ), and M2, ( b ) and ( c ), of Table . Lumped-capacitance modeling results are also shown in ( a ) and ( b ). \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$T_\text {f1}$$\end{document} and \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$T_\text {f2}$$\end{document} are frozen product temperatures for different center vials; \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$T_\text {vw}$$\end{document} represents the temperature of the vial wall’s outer surface. Model curves terminate at the predicted end of drying. Case M1 in ( a ) was used to tune the four microwave-related parameters, and Case M2 is a validation case.](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_0371/pmc11950371/pmc11950371__41598_2025_91642_Fig8_HTML.jpg)
![Experimentally measured temperatures and pressures for Cases SM1 and SM2 of Table , shown in ( a , c ) and ( b , c ) respectively. Lumped-capacitance model simulations are also shown in ( a ) and ( b ). \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$T_\text {f1}$$\end{document} , \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$T_\text {f2}$$\end{document} , and \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$T_\text {f3}$$\end{document} are product temperature readings in different center vials; \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$T_\text {vw}$$\end{document} is the temperature measured on the outside wall of a vial. Model curves terminate at predicted end of primary drying. In ( a ), the model \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$R_{p}$$\end{document} was adjusted to match product temperature readings. All microwave-related parameters are determined from Case M1 in Fig. below, so Case SM2 in ( b ) has no tuning parameters.](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_0371/pmc11950371/pmc11950371__41598_2025_91642_Fig5_HTML.jpg)
![Experimentally measured temperatures, ( a ), and pressures, ( b ), for the SM3 case of Table , with lumped-capacitance modeling results also shown in ( a ). \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$T_\text {f1}$$\end{document} , \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$T_\text {f2}$$\end{document} , and \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$T_\text {f3}$$\end{document} are frozen product temperatures for different center vials. Model curves terminate at predicted end of drying. No parameter tuning was carried out based on these experimental results, so this serves as a validation case for the model.](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_0371/pmc11950371/pmc11950371__41598_2025_91642_Fig6_HTML.jpg)
![Overlaid 13 C SSNMR spectra of lyophilized attenuated live virus vaccine formulations with regions used for \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$^1H$$\end{document} \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$T_1$$\end{document} and \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$^1H$$\end{document} \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$T_{1\rho }$$\end{document} relaxation time analysis highlighted. Conventional results are from Cycle V1, and RF/Microwave results are from Cycle V2.](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_0371/pmc11950371/pmc11950371__41598_2025_91642_Fig11_HTML.jpg)
![Solid-state NMR \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$^1H$$\end{document} \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$T_1$$\end{document} and \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$^1H$$\end{document} \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$T_{1\rho }$$\end{document} relaxation times for attenuated live virus formulations.](https://pub-med-central-html-table-images-cdn.bioz.com/pub_med_central_ids_ending_with_0371/pmc11950371/pmc11950371__Tab6__lab_ascii32_scale_ascii32_lyophilizer__sp_ascii32_industries.jpg)